Myriad Genetics (MYGN) Announces Earnings Results
Myriad Genetics (NASDAQ:MYGN) announced its quarterly earnings data on Monday. The company reported $0.31 EPS for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.07, Bloomberg Earnings reports. The firm had revenue of $194.00 million for the quarter, compared to analyst estimates of $188.72 million. Myriad Genetics had a return on equity of 9.54% and a net margin of 13.28%. The business’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same period last year, the company earned $0.26 EPS.
Myriad Genetics (NASDAQ MYGN) opened at $35.81 on Wednesday. Myriad Genetics has a 12-month low of $15.15 and a 12-month high of $41.57. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.34 and a quick ratio of 2.06. The stock has a market capitalization of $2,381.88, a price-to-earnings ratio of 31.56, a PEG ratio of 2.17 and a beta of 0.32.
A number of brokerages have commented on MYGN. BTIG Research set a $41.00 price objective on Myriad Genetics and gave the company a “buy” rating in a research report on Tuesday, January 16th. BidaskClub upgraded Myriad Genetics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 20th. Goldman Sachs Group began coverage on Myriad Genetics in a research report on Monday, January 29th. They issued a “sell” rating and a $32.00 price objective on the stock. ValuEngine lowered Myriad Genetics from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd. Finally, Barclays reiterated a “hold” rating and issued a $30.00 price objective on shares of Myriad Genetics in a research report on Monday, January 8th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $30.67.
About Myriad Genetics
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.